IJCS | Volume 33, Nº4, July and August 2020

418 11. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Feb 28;382:1708-20. 12. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus disease 2019 (covid-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020 Mar 10;172(9):577-82. 13. Zhu H, Rhee JW, Cheng P, Waliany S, Chang A, Witteles RM, Maecker H, Davis MM, Nguyen PK, Wu SM. cardiovascular complications in patients with COVID-19: Consequences of viral toxicities and host immune response. Curr Cardiol Rep. 2020;22(5):32. 14. Atri D, Siddiqi HK, Lang J, Nauffal V, Morrow DA, Bohula EA. COVID-19 for the cardiologist: a current review of the virology, clinical epidemiology, cardiac and other clinical manifestations and potential therapeutic strategies. JACC Basic Transl Sci. 2020; 5(5):518-36. 15. Jorge AL, Rosa ML, Martins WA, Correia DM, Fernandes LC, Costa JA, et al. the prevalence of stages of heart failure in primary care: a population-based study. J Card Fail.2016;22(2):153-7. 16. Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail. 2011;13(1):18-28. 17. Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, et al. Systolic and diastolic heart failure in the community. JAMA 2006;296(18):2209-16. 18. ChapmanAR, BulargaA, Mills NL. High sensitivity cardiac troponin can be an ally in the fight against COVID-19. Circulation. 2020;141(22):1733-5. 19. Chieffo A, Stefanini GG, Price S, Barbato E, Tarantini G, Karam N, et al. EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic. Eur Heart J 2020;41(19):1839-51. 20. Tadic, M., Cuspidi, C. Obesity and heart failure with preserved ejection fraction: a paradox or something else?. Heart Fail Rev. 2019 ; 24(3):379-85. 21. Frühbeck G, Baker J, L, Busetto L, Dicker D, Goossens GH, Holford JCG, et al. European Association for the Study of Obesity Position Statement on the Global COVID-19 Pandemic. Obes Facts. 2020;13(2):292-6. 22. Ernande L, Audureau E, Christine CL, Bergerot C, Henegar C, Sawaki D, et al. Clinical implications of echocardiographic phenotypes of patients with diabetes mellitus. J Am Coll Cardiol. 2017;70(14):1704-16. 23. Bornstein JF, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, et al. Practical recommendation for the management of diabetes in patients with COVID 19. Lancet Diabetes Endocrinol. 2020 Apr 23. pii: S2213-8587(20)30152-2. doi: 10.1016/S2213-8587(20)30152-2. 24. Xue T, Li Q, Zhang Q, Lin W, Wen J, Li L, et al. Blood glucose levels in elderly subjects with type 2 diabetes during COVID-19 outbreak: a retrospective study in a single center. medRxiv 2020; published online April 2; DOI:10.1101/2020.03.31.20048579. 25. HoffmannM, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2. Cell 2020;181(2):271-80.e8. 26. Sociedade Brasileira de Endocrinologia e Metabologia. Posicionamento em Conjunto sobre Uso de Inibidores da SGLT2. Disponível em https://www.endocrino.org.br/posicionamento-em- conjunto-sobre-uso-de-inibidores-da-sglt2/. Acesso em 01/05/2020. 27. Epelman S, Shrestha K, Troughton RW, Francis GS, Sen S, Klein AL, Tang WH. Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail;2009;15(7): 565–71. 28. Batlle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin Sci (Lond). 2020;134(5):543-5. 29. Cadegiani FA. Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?Am J Physiol Endocrinol Metab. 2020;18(5):E587-E6. 1;318:E587-E588. doi: 10.1152/ajpendo.00136.2020. 30. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. 2020 May 1;382(29):e10-102. 31. ManciaG,ReaF,LudergnaniM,ApoloneG,CorraoG.Renin‑Angiotensin- Aldosterone System Blockers and the Risk of Covid-19. N Engl J Med. 2020 May ;382(25):431-40. 32. Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB et al. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med. 2020 May 1;382(25):2441-8. 33. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Et al; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383-92. 34. Malachias MVB, SouzaWKSB, Plavnik FL, Rodrigues CIS, BrandãoAA, Neves MFT, et al. 7ª Diretriz Brasileira de HipertensãoArterial. Arq Bras Cardiol 2016; 107(3Supl.3):1-83. 35. Zhang H, Liu G, Zhou W, Zhang W, Wang K, Zhang J. Neprilysin inhibitor–angiotensin II receptor blocker combination therapy (sacubitril/ valsartan) suppresses atherosclerotic plaque formation and inhibits inflammation in apolipoprotein E-deficient Mice. Sci Rep 2019;9(1):6509. 36. Acanfora D, Ciccone MM, Scicchitano P, Acanfora C, Casucci G. Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients. Eur Heart J Cardiovasc Pharmacother. 2020;6(3):135-6. 37. Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9(1):29. 38. Sociedade Brasileira de Cardiologia. Comitê Coordenador da Diretriz de Insuficiência Cardíaca. Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda. Arq Bras Cardiol. 2018;111(3):436-539. 39. Solomon SD, McMurray JJV,Anand IS, Ge J, LamCSP, MaggioniAP, et al. PARAGON-HF Investigators and Committees. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019 Sep 1;381(17):1609-20. 40. Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020;6736(20)3180-6. 41. Baguet JP, Tremel F, Fabre M. Chloroquine cardiomyopathy with conduction disorders. Heart. 1999;81(2):221-3. 42. Bae SM, Jung HO, Ihm SM, Kim JJ, Chin JY, Kim TS, et al. Hydroxychloroquine-induced cardiomyopathy that presented as pulmonary hypertension: a newly noted complication. Cardiology. 2012;123(3):197-200. 43. VereckeiA, FazakasA, Balo T, Fekete B, MolnarMJ, Karadi I. Chloroquine cardiotoxicity mimicking connective tissue disease heart involvement. Immunopharmacol Immunotoxicol. 2013;35(2):304-6. 44. Yogasundaram H, Putko BN, Tien J, Paterson DI, Cujec B, Ringrose J, et al. Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment. Can J Cardiol. 2014;30(12):1706-15. 45. YogasundaramH, HungW, Paterson ID, Sergi C, Oudit GY. Chloroquine- induced cardiomyopathy: a reversible cause of heart failure. Esc Heart Fail. 2018;5(3):372-5. 46. Tarantini L, Navazio A, Cioffi G, Turiano G, Colivicchi F, Gabrielli D. [Being a cardiologist at the time of SARS-COVID-19: is it time to reconsider our way of working?]. G Ital Cardiol (Rome). 2020;21(5):354-7. 47. Lopes MAC, Oliveira GMM, Ribeiro ALP, Pinto FJ, Rey HCV, Zimerman LI, et al. Diretriz da Sociedade Brasileira deCardiologia sobre Telemedicina na Cardiologia – 2019. Arq Bras Cardiol. 2019;113(5):1006-56. Mesquita et al. HFpEF and COVID-19 Int J Cardiovasc Sci. 2020; 33(4):412-418 Viewpoint This is an open-access article distributed under the terms of the Creative Commons Attribution License